Targeted radiation plus hormone therapy shows promise against resistant prostate cancer

NCT ID NCT04419402

Ongoing Disease control Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial investigates whether adding a targeted radiation therapy called Lu-PSMA to the standard hormone drug enzalutamide can delay cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. Participants receive either enzalutamide alone or enzalutamide plus four doses of Lu-PSMA over 24 weeks. The study measures how long it takes for PSA levels to rise, indicating cancer growth, and tracks imaging results and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu-PSMA (177Lu-PSMA-617) and enzalutamide
What this could lead to: If successful, this combination could offer a new treatment option that delays cancer progression in men with advanced prostate cancer who have not yet had chemotherapy.
What could go wrong: This is a phase 2 trial with a relatively small number of participants, so results may not confirm benefit. Adding Lu-PSMA may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Austin Health

Heidelberg, Victoria, 3084, Australia
Calvary Mater Newcastle

Newcastle, New South Wales, 2298, Australia
Chris O'Brien Lifehouse

Camperdown, New South Wales, 2050, Australia
Fiona Stanley Hospital

Perth, Western Australia, 6150, Australia
Liverpool Hospital

Liverpool, New South Wales, 2170, Australia
Macquarie University Hospital

Macquarie Park, New South Wales, 2109, Australia
Monash Health

Clayton, Victoria, 3168, Australia
Northern Cancer Institute

Sydney, New South Wales, 2065, Australia
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3002, Australia
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Royal Brisbane and Women's Hospital

Brisbane, Queensland, 4029, Australia
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
St George Hospital

Kogarah, New South Wales, 2217, Australia
St Vincents Hospital

Darlinghurst, New South Wales, 2010, Australia
The Alfred Hospital

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.